Introduction
============

Cerebral infarction (CI) has the characteristics of long recovery time and unsatisfactory prognosis. The disease progresses gradually or stepwise, and is the main cause of human disability and death ([@b1-etm-0-0-7859]). In recent years, the number of people who died or became disabled from cerebral infarction has shown an upward trend.

Clinical treatment of cerebral infarction often uses thrombolysis technology. Reperfusion after thrombolysis is beneficial to the recovery of neurons in reversible damage in the ischemic area, leading to brain microvascular damage, blood-brain barrier (BBB) injury, and angiogenic brain edema, aggravating brain damage, which are also serious complications of thrombolysis, so protecting or reducing BBB injury is of great significance for the treatment of cerebral infarction. BBB is a special barrier between the blood circulation and nerve tissue of the brain. Its function is to maintain the homeostasis of the brain and regulate the balance of material exchange in the brain. BBB injury is the main cause of vasogenic cerebral edema and worsening of the disease in ischemic stroke, maintenance and improvement of BBB damage are important for the treatment of ischemic stroke and improvement of prognosis ([@b2-etm-0-0-7859]--[@b4-etm-0-0-7859]). The nuclear transcription factor NRF-2/hemeoxygenase 1 (NRF-2/HO-1) signaling pathway is the most important cell defense mechanism, and studies have shown that NRF-2/HO-1 signaling pathway activation can improve the integrity and stability of the BBB, and is a key target for the treatment of BBB in cerebral infarction ([@b5-etm-0-0-7859],[@b6-etm-0-0-7859]). Edaravone is a clinically used drug for the treatment and prevention of ischemic stroke. It inhibits delayed neuronal death, and inhibits the production of lipid peroxide, damage of vascular endothelial cells and ischemic cerebral edema and improves neurological function ([@b7-etm-0-0-7859],[@b8-etm-0-0-7859]), there are reports that edaravone also has effects in improving BBB, but the mechanism is still unclear ([@b9-etm-0-0-7859],[@b10-etm-0-0-7859]), and opinions vary. Niu *et al* ([@b11-etm-0-0-7859]) considered that edaravone inhibits the expression of occludin around the injured area of BBB, and Tsuruoka *et al* ([@b12-etm-0-0-7859]) that the expression of MMP-9 inhibited damaged brain tissue to protect the function of BBB. However, the relationship between edaravone and NRF-2/HO-1 signaling pathway has rarely been reported.

The aim of the study was to investigate the effect of edaravone on the treatment of ischemic stroke with BBB injury and the influence on NRF-2/HO-1 signaling pathway, in order to provide a reference for the clinical treatment of ischemic stroke with edaravone.

Materials and methods
=====================

### Test animals

Eighty adult healthy male SD rats, with body weight of 200--250 g, were provided by Hunan Weitong Lihua Experimental Animal Co., Ltd., animal certificate number: SCXK (Hunan) 2009-0004. After 1 week of adaptive feeding, the experiment was carried out. During the feeding period, the rats were given free access to water, with constant temperature and humidity, and artificial lighting for 12 h each day. All the operations strictly abided by the ethical rules for experimental animals.

The study was approved by the Ethics Committee of The Third Affiliated Hospital of Qiqihar Medical University (Qiqihar, China).

### Permanent cerebral artery occlusion model and evaluation

A modified Longa method was used to make a permanent middle cerebral artery occlusion model (cerebral infarction rats): after abdominal anesthesia, rats were fixed on the operating table in supine position, with preserved skin sterilized. Then 1 cm median incision of the neck was taken to bluntly separate the neck, and the right common carotid artery (CCA), external carotid artery (ECA) and internal carotid artery (ICA)were separated, ECA trunk was separated, ligated 2 mm from the CCA bifurcation and separated, continuing to separate from the ICA to the base of the skull, the ICA was exposed, CCA was temporarily clamped, a small opening was cut in the ECA stump, the suture was inserted into the ICA through the ECA stump, when slight resistance of the incoming suture was felt, the end of the filament suture was ligated and cut, CCA blood flow was restored, and wounds were sutured. After successful model preparation, the rats were sacrificed at 24 h after surgery for neurological function scores, and ≥2 were selected as study subjects. Neurological function score: 0 point, no neurological deficit; 1 point, the left forelimb of the rat was difficult to fully extend; 2 points, left front limb flexion; 3 points, slightly to the left when walking; 4 points, severe left side turn; 5 points, rats fell to the left while walking.

### Grouping and administration

Eighty rats with cerebral infarction were randomly divided into 4 groups: cerebral infarction model group, edaravone low, medium and high dose groups. Healthy rats were taken from the same batch as sham operation group, the rat model was established in the same way as the 'permanent middle cerebral artery occlusion model', but only the vascular was separated and the filament suture was not inserted (n=20 per group). Rats in the cerebral infarction model group and the control group were given normal saline by intragastric administration. The edaravone low, medium and high dose groups were intragastrically administered with 10, 15 and 20 mg/kg, respectively, for 14 days.

Indicator detection
-------------------

### Survival status

The survival status of all the groups of rats was recorded, including activity, fur and diet.

### Body mass and neurological function scores

The body mass and neurological function scores of all the groups of rats before and after administration were recorded. The neurological function score was the same as above.

### Brain tissue water content

After treatment, 10 rats in each group were sacrificed, and the brain tissue of the first half of the hematoma center was taken, weighed and placed in an oven at about 100°C for 24 h and the dry weight was recorded. The water content of brain tissue was calculated as follows: brain tissue water content (%) = (fresh mass - dry mass)/fresh mass 100%.

### Blood-brain barrier permeability

The Evans blue formamide (EB) method was used. After treatment, the remaining 10 rats in each group were taken. After general anesthesia, 2 ml/kg of 2% EB was injected through the tail vein. The thoracic left ventricle was perfused with normal saline at a pressure of 110 mmHg until the liquid flowing out of the right atrium was colorless. The brain was taken by decapitation, and the inner part of the hematoma was weighed and placed in formamide, 1 ml/100 g of brain tissue, and incubated at 60°C overnight. After centrifugation at 300 × g and 4°C for 10 min with a radius of 8 cm, the OD value of the supernatant was determined by UV751GD ultraviolet spectrophotometer (Shanghai Precision Scientific Instrument Co., Ltd.) at a wavelength of 632 nm, and the EB level was calculated. The higher the EB, the higher the blood-brain barrier permeability.

### Western blot analysis of NRF-2 and HO-1 protein expression

The total protein in remaining hematoma brain tissue was extracted by RIPA buffer, and was detected by BCA method. Then, 10% SDS-PAGE was performed and transferred to a PVDF membrane and 30 µg of protein was loaded per lane. The cells were blocked with 5% skim milk powder at 4°C for 1 h. NRF-2 (1:250) and HO-1 (1:2,000) primary antibodies were added dropwise and incubated overnight. The antibodies were incubated again and visualized with horseradish enzyme-labeled secondary antibody (1:2,000) prior to scanning by a Bio-Rad 2000 gel imaging system. Absorbance values were analyzed using the Image-Pro Plus 6.0 Quantityone software. NRF-2 (bs-1074R-1) and HO-1 (bs-0827R-1) were rabbit anti-human antibodies and were from Shanghai Hengfei Biotechnology Co., Ltd. β-actin (item no.: SC.1616, Santa Cruz, Biotechnology, Inc.) was the internal reference.

### Oxidative stress index

After treatment of rats in all the groups, blood was taken from ocular venous plexus prior to euthanasia, and the serum was obtained via centrifugation at 4,000 × g at 25°C for 5 min. ELISA method was performed and the OD values of malonyldialdehyde (MDA), superoxide dismutase (SOD) and glutathione (GSH) in serum was read by MRX Revelation type microplate reader (Dynex) according to the kit instructions, the expression levels were determined by the standard curve of each index. MDA, SOD and GSH kits were purchased from Nanjing Jiancheng Bioengineering Co., Ltd.

### Statistical analysis

The data were processed by SPSS statistical software package (SPSS, Inc.). Measurement data, such as NRF-2 and HO-1 protein relative expression, were expressed as mean standard deviation (mean ± SD), and intra-group comparison was performed using variance analysis. The SNQ-q test was used for pairwise comparison between groups, α=0.05 for the test level. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Survival status of the five groups of rats

The rats in the sham operation group were active, the diet was normal, the hair color was regular, sensitive to external stimuli, the activity of rats with cerebral infarction was significantly reduced, the diet was significantly reduced, the hair color of the rats was poor, and the spirit and aggression both were poor, and the state of the edaravone rats was improved to a different extent than that of cerebral infarction rats.

### Comparison of the body weight, neurological function score, brain tissue water content and blood-brain barrier permeability of the five groups of rats

Compared with the control group, the body mass of the cerebral infarction model group was significantly reduced after treatment (t=13.937, P\<0.001), neurological function score (t=14.623, P\<0.001), brain tissue water content (t=19.711, P\<0.001) and blood-brain barrier permeability (t=26.068, P\<0.001) were significantly increased. Compared with the cerebral infarction model group, the body weight of the edaravone group was significantly increased after treatment (F=31.122, P\<0.001), neurological function score (F=29.474, P\<0.001), brain tissue water content (F=60.185, P\<0.001) and blood-brain barrier permeability (F=22.986, P\<0.001) were significantly reduced, and showed a dose-dependent trend ([Figs. 1](#f1-etm-0-0-7859){ref-type="fig"} and [2](#f2-etm-0-0-7859){ref-type="fig"}).

### Expression of NRF-2 and HO-1 in the brain of five groups of rats

Compared with the control group, the expression of NRF-2 (t=2.460, P=0.036) and HO-1 (t=2.683, P=0.025) in the brain infarction model was significantly increased. Compared with the cerebral infarction model group, the expression of NRF-2 (F=21.481, P\<0.001) and HO-1 (F=65.333, P\<0.001) in the edaravone group was significantly increased and in a dose-dependent manner ([Fig. 3](#f3-etm-0-0-7859){ref-type="fig"}).

### Comparison of oxidative stress indicators in the peripheral blood of five groups of rats

Compared with the control group, the MDA (t=10.646, P\<0.001) in the cerebral infarction model group were significantly increased, and the GSH (t=49.40, P=0.001) and SOD (t=9.916, P\<0.001) were significantly decreased, and compared with the brain infarction model group, the MDA (F=19.051, P\<0.001) was significantly lower in the edaravone group, and the GSH (F=9.667, P\<0.001) and SOD (t=17.374, P\<0.001) were significantly increased, with a dose-dependence trend ([Fig. 4](#f4-etm-0-0-7859){ref-type="fig"}).

Discussion
==========

Cerebral edema after cerebral infarction is vasogenic cerebral edema caused by impaired BBB, increased permeability and plasma exudation, and the cells secrete a large number of reactive oxygen species (ROS), which can participate in oxidative stress and the release of cytotoxic substances, as shown in the results of this study, the survival state of rats with cerebral infarction decreased, the brain water content increased, while the MDA of peripheral blood with oxidative stress were significantly increased, and the antioxidant GSH and SOD were significantly reduced.

The NRF2/HO-1 pathway is an important antioxidant and cytotoxic defense mechanism in cells, which is of great significance in stabilizing and protecting the integrity of the blood-brain barrier. Under physiological conditions, the molecular chaperone Kelch-like epichlorohydrin-related protein-1 (Keapl) is coupled with NRF2, binds to actin, rapidly degraded by ubiquitination, and has a short half-life. Under oxidative stress conditions such as ischemia and hypoxia, NRF2 is decoupled from Keap, and a large number of NRF2s are activated to enter the nucleus and initiate NRF2 downstream target gene expression. As a brain protective factor, NRF-2, through the binding of cell stress signaling proteins, participates in the transcription process, and then regulates the expression of various detoxification enzymes and antioxidant enzymes downstream, which can regulate oxidative stress after cerebral infarction ([@b13-etm-0-0-7859]). HO-1 is an important downstream target gene of NRF2. HO-1 catalyzes the degradation of heme, and the products of degradation have anti-oxidative damage function. It has anti-inflammatory, anti-apoptotic and anti-proliferative synergistic effects on HO-1. It plays an important protective role in various diseases.

A large number of studies have shown that activation of the NRF2/HO-1 pathway and induction of high expression of NRF2 and/or HO-1 may play an important role in anti-oxidation, anti-apoptosis and protection of the blood-brain barrier ([@b14-etm-0-0-7859]). The results of this study showed that compared with the control group, the expression of NRF2 and HO-1 protein in the brain of rats with cerebral infarction increased, suggesting that the NRF2/HO-1 pathway is activated, which is the endogenous and adaptive protection mechanism of the body to initiate cerebral infarction, but this compensatory ability is relatively limited, no drug intervention, no improvement in neurological function scores in rats, suggesting that nerve function may be lost, brain tissue damage may occur, with the administration of edaravone and increased dose of edaravone, the expression of NRF2 and HO-1 protein in the brain increase in a dose-dependent manner, edaravone may promote the decoupling of NRF2 from the cytoplasmic chaperone Keap through the pathway of inhibiting apoptosis, transport to the nucleus, initiate the relative expression of the downstream gene HO-1 of NRF2, promote the body to exert stronger anti-oxidative stress, improve the integrity of BBB, and then protect the cranial nerves of infarcted rats ([@b15-etm-0-0-7859]). This result is similar to that reported in the literature. For example, studies of Liu *et al* ([@b16-etm-0-0-7859]) have shown that edaravone protects the hippocampal neurons of kainic acid-induced epileptic rats by activating Nrf2/HO-1 channels; Zhang *et al* ([@b17-etm-0-0-7859]) considered that edaravone reduces neuronal apoptosis in the hippocampus by activating the Nrf2/HO-1 signaling pathway, which in turn produces neuroprotection in a mouse model of pneumococcal meningitis. Cechetti *et al* ([@b18-etm-0-0-7859]) reported that edaravone reduces oxidative stress induced by chronic cerebral hypoperfusion injury and is associated with activation of Nrf2/HO-1 signaling pathway.

There is insufficient research on this topic *in vivo*, although the administration of edaravone in rats with cerebral infarction reduces the permeability of blood-brain barrier and brain edema, increases the expression of Nrf2 and HO-1 protein in brain tissue, whether the upregulation of Nrf2 and HO-1 protein expression is a direct or indirect effect of edaravone is not clear, and further studies should be combined with *ex vivo* analysis.

In summary, edaravone may exert a blood-brain barrier protection by activating the NRF-2/HO-1 signaling pathway.
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